Current challenges to underpinning the genetic basis for cholangiocarcinoma.
Current challenges to underpinning the genetic basis for cholangiocarcinoma.
复制标题
DOI：
10.1080/17474124.2021.1915128
复制
发表时间：
2021-05
影响因子：
3.9
通讯作者：
Calvisi DF
中科院分区：
文献类型：
--
作者：
Cigliano A;Chen X;Calvisi DF
Cholangiocarcinoma (CCA) is an aggressive cancer type with a dismal prognosis. CCA typically presents at an advanced stage when surgical resection is not feasible, and systemic chemotherapy is generally of limited benefit. Thus, developing effective therapies against this deadly tumor is imperative and remains an unmet need. To provide more effective treatment options, high-throughput approaches have been employed, leading to a better delineation of each CCA subtype’s genomic and transcriptomic landscape as well as the identification of promising candidates for targeted, personalized therapies. In this scenario, the recent approval of pemigatinib, a pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, for the treatment of the CCA subtype characterized by FGFR2 mutations, represents the first of (presumably) numerous novel therapeutic approaches against this aggressive disease. This review provides an overview regarding the current scenario and knowledge of the genomic landscape occurring in CCA and the potentially actionable molecular aberrations in each CCA subtype. The establishment and advances of high-throughput methodologies applied to genetic and epigenetic profiling are changing the therapeutic landscape of many cancer types, including CCA. These approaches have led to the generation of a large body of data that must be interpreted appropriately and eventually implemented in clinical practice. The following advancements towards precision medicine in CCA management will require designing better clinical trials with improved methods to stratify biliary tumor patients.
登录
查看更多内容
影响因子：
13.5
作者：
Braconi, Chiara;Huang, Nianyuan;Patel, Tushar
通讯作者：
Patel, Tushar
DOI：
10.1016/s1470-2045(20)30157-1
发表时间：
2020-06
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Abou-Alfa GK;Macarulla T;Javle MM;Kelley RK;Lubner SJ;Adeva J;Cleary JM;Catenacci DV;Borad MJ;Bridgewater J;Harris WP;Murphy AG;Oh DY;Whisenant J;Lowery MA;Goyal L;Shroff RT;El-Khoueiry AB;Fan B;Wu B;Chamberlain CX;Jiang L;Gliser C;Pandya SS;Valle JW;Zhu AX
通讯作者：
Zhu AX
影响因子：
65.1
作者：
Banales, Jesus M.;Cardinale, Vincenzo;Alvaro, Domenico
通讯作者：
Alvaro, Domenico
影响因子：
4.2
作者：
Gradilone SA;O'Hara SP;Masyuk TV;Pisarello MJ;LaRusso NF
通讯作者：
LaRusso NF
新型靶基因和针对胆管癌鉴定的有效生物标志物面板。
影响因子：
3.7
作者：
Andresen K;Boberg KM;Vedeld HM;Honne H;Hektoen M;Wadsworth CA;Clausen OP;Karlsen TH;Foss A;Mathisen O;Schrumpf E;Lothe RA;Lind GE
通讯作者：
Lind GE